HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On January 9, 2018, Halozyme Therapeutics, Inc., a Delaware corporation (“Halozyme”), issued a press release (the “Press Release”) which contained information related to Halozyme’s expected 2017 royalty revenue and year-end cash balance. A copy of the Press Release is attached hereto as Exhibit 99.1.
On January 9, 2018, Halozyme presented at the annual JP Morgan Healthcare Conference, providing a corporate update on certain strategic programs and financial guidance for 2018. The presentation contained information related to various aspects of Halozyme’s expected 2017 results of operations and financial condition. A copy of the slides used in this presentation is attached hereto as Exhibit 99.2.
Exhibits 99.1 and 99.2 are furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 7.01 Regulation FD Disclosure.
The Press Release and slides from the JP Morgan Healthcare Conference presentation attached hereto as Exhibits 99.1 and 99.2, respectively, provide a corporate update on certain strategic programs and financial guidance for 2018 and are incorporated herein by reference. The slides attached hereto as Exhibit 99.2 (as well as the information contained therein) are expected to be used in subsequent presentations to interested parties, including analysts and stockholders.
This information is being furnished to Item 7.01 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed to Regulation FD.
Please refer to the Press Release attached hereto as Exhibit 99.1 and slide 2 of the presentation attached hereto as Exhibit 99.2 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.
Item 9.01. Financial Statements and Exhibits.
Exhibits
Exhibit No.Description
HALOZYME THERAPEUTICS INC ExhibitEX-99.1 2 ex991jpm1918pressrelease.htm EXHIBIT 99.1 JPM PRESS RELEASE Exhibit EXHIBIT 99.1Contacts:Jim [email protected] [email protected] PORJECTS 25 TO 30 PRECENT ENHANZE ROYALTY GROWTH IN 2018 CONTINUES TO EXPECT TARGET NUMBER OF PFS EVENTS IN HALO-301 REGISTRATION TRIAL TO BE REACHED IN LATE Q4SAN DIEGO,…To view the full exhibit click here
About HALOZYME THERAPEUTICS, INC. (NASDAQ:HALO)
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. Its development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
